A Study in Radiotherapy-related Nervous System Complications

NCT03908502 · tracked via the Priya Life Science China tracker

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Phase

Observational

Started

2017-06-01

Last updated

2023-07-25

Condition(s) studied

Nervous System Complication

Study summary

Purpose: This observational study aims to evaluate the clinical manifestations, therapeutic effects, progress and prognosis in radiotherapy-related nervous system complications.

OUTLINE: This is an observational clinical trial. Patients are enrolled and administrated with optimized clinical treatment. Blood, urine, stool, cerebrospinal fluid (CSF), imaging and other examinations, and scale assessments are regularly performed to evaluate the state of the disease.

Further study details are provided by Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University/Yamei Tang.

Primary outcome measure: The primary endpoint is overall survival.

Eligibility

Sex

ALL

Min age

0 Years

Max age

—

Healthy volunteers

Inclusion Criteria * Receipt of radiotherapy Exclusion Criteria * Inability to sign a written informed consent.

Primary outcome measure(s)

Overall Survival (OS) — Baseline until death or up to Year 20
Overall survival is the duration between the first day of study enrollment to death. For participants who are alive, overall survival is censored at the last contact.

Trial sites (1)

Facility	City	Region	Status
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University	Guangzhou	Guangdong	Recruiting

More Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University trials in China

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer Active, not recruiting

OPtimizing REperfusion by Primary Intra-Arterial ThRomboLysis for Medium Vessel Occlusion Recruiting

Mycophenolate Mofetil in Gastrointestinal Henoch-Schonlein Purpura Recruiting

The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery Recruiting

Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03908502 on ClinicalTrials.gov ↗ ← All trials in China